drugset / Trial / NCT00662883

Assessing the Effects of a Nasal Corticosteroid on PMI-150 (Intranasal Ketamine)

NCT00662883

Phase 1 Completed 18 enrolled Javelin Pharmaceuticals
NaSingle-groupOpen-label

Summary

To assess the effects of nasal corticosteroid treatment on the rate and extent of intranasal absorption of PMI-150 (intranasal ketamine HCl)

Timeline

Start
2007-11
Primary completion
2008-02
Completion
2008-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule 30 mg Intranasal
Subject Mometasone furoate Other / unclassified Intranasal

Indications

No indication recorded.